Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein

Heidi Schwarzenbach1*, Corinna Eichelser1, Bettina Steinbach1, Josefine Tadewaldt1, Klaus Pantel1, Victor Lobanenkov2 and Dmitri Loukinov2

Abstract

Background: As cancer-testis MAGE-A antigens are targets for tumor immunotherapy, it is important to study the regulation of their expression in cancers. This regulation appears to be rather complex and at the moment controversial. Although it is generally accepted that MAGE-A expression is controlled by epigenetics, the exact mechanisms of that control remain poorly understood.

Methods: We analyzed the interplay of another cancer-testis gene, BORIS, and the transcription factors Ets-1 and Sp1 in the regulation of MAGE-A1 gene expression performing luciferase assays, quantitative real-time PCR, sodium bisulfite sequencing, chromatin immunoprecipitation assays and pull down experiments.

Results: We detected that ectopically expressed BORIS could activate and demethylate both endogenous and methylated reporter MAGE-A1 promoter in MCF-7 and micrometastatic BCM1 cancer cell lines. Overexpression of Ets-1 could not further upregulate the promoter activity mediated by BORIS. Surprisingly, in co-transfection experiments we observed that Sp1 partly repressed the BORIS-mediated stimulation, while addition of Ets-1 expression plasmid abrogated the Sp1 mediated repression of MAGE-A1 promoter. Both BORIS and Sp1 interacted with the TATA binding protein (hTBP) suggesting the possibility of a competitive mechanism of action between BORIS and Sp1.

Conclusions: Our findings show that BORIS and Sp1 have opposite effects on the regulation of MAGE-A1 gene expression. This differential regulation may be explained by direct protein-protein interaction of both factors or by interaction of MAGE-A1 promoter with BORIS alternatively spliced isoforms with different sequence specificity. We also show here that ectopic expression of BORIS can activate transcription from its own locus, inducing all its splice variants.

Keywords: DNA methylation, Histone modifications, Promoter activation, Protein protein interaction

Background

Based on their pronounced tumor specificity, cancer-testis antigens (CTA) which comprise numerous gene families, such as MAGE-A, are particularly promising targets for specific anti-cancer immunotherapy. Clinical studies have demonstrated vaccination-induced T-cell mediated responses in cancer patients by CTA [1]. The MAGE-A gene family comprising 12 members (MAGE-A1-12) is located on chromosome X [2]. With the exception of testicular germ cells (spermatogonia and primary spermatocytes) and placenta, they are silent in normal somatic tissues, but expressed in numerous epithelial carcinomas and leukemia [3]. Nevertheless, the MAGE-A protein levels can vary widely in tumors, and not all tumors express these antigens. Previous studies revealed that control of MAGE-A expression is rather complex and to a large extent poorly understood. The restricted expression pattern of MAGE-A antigens is regulated by epigenetic mechanisms [4]. Methylation of CpG dinucleotides on the MAGE-A1 promoter prevents access

* Correspondence: hschwarz@uke.uni-hamburg.de
1Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany
Full list of author information is available at the end of the article

http://creativecommons.org/licenses/by/4.0/
ties. These alternative transcripts have the potential to enable binding activities and varying transcriptional properties to be characterized, exhibiting differential DNA expression profiles in normal germ line and cancer cells (untranslated regions) [16]. So far, 23 BORIS splice variants with distinct regions have been identified and are involved in the transcriptional repression of methylated DNA [10]. We observed that among the MBDS, the variant MBD1v1 of the five MBD1 isoforms has the ability to repress the unmethylated MAGE-A1 promoter and downregulate Ets-mediated transcriptional activation [11]. This MBD1v1-mediated downregulation of MAGE-A1 gene expression is dependent on three CXXC domains, which additionally repress unmethylated promoters [12]. Conversely, we showed that MBD2a may enhance the basal promoter activity of MAGE-A1 [11]. In line with our observation, a previous report demonstrated that the longer form of MBD2, the isoform MBD2a, is not only involved in gene repression but also in promoting activation of the unmethylated cAMP-responsive genes by interaction with the RNA helicase A, and accordingly, MBD2a may be either a transcriptional activator or repressor [13].

The ectopic expression of BORIS (Brother of the Regulator of Imprinted Sites), the mammalian CTCF paralog, may induce the expression of MAGE-A1 gene [14]. Like MAGE-A1, BORIS is a CTA, and in addition to its normal expression in male germ cells, BORIS is expressed in various solid tumors, with frequent co-expression of other CTAs [15]. The transcription of BORIS is regulated by three alternative promoters (A, B, C) utilizing five distinct 5’UTRs (untranslational regions) [16]. So far, 23 BORIS splice variants with distinct expression profiles in normal germ line and cancer cells have been characterized, exhibiting differential DNA binding activities and varying transcriptional properties. These alternative transcripts have the potential to encode 17 distinct proteins with varying number of zinc fingers in the DNA binding domain and different combinations of amino- and carboxy-termini. In vitro binding of BORIS isoforms to DNA targets can be methylation-sensitive and depends on the number and specific composition of zinc fingers. Nine of the 17 in vitro translated BORIS isoproteins bound the H19 ICR CTCF target site, whereas the remaining other 8 BORIS isoforms did not. The presence of a specific long amino terminus in the different isoforms is necessary and sufficient to activate the testis-specific cerebroside sulfotransferase (CST) transcription. Accordingly, isoforms B2, B3, B4 and B5 lacking this long amino terminus could bind to CST, but did not induce transcription above background level [17]. Recent experiments in cell lines suggested that BORIS expression is sufficient to simultaneously demethylate and activate the transcription of CTAs and oncogenes [14, 18, 19]. However, analyses of melanoma tissue samples, where MAGE-A1 may be expressed in the absence of BORIS, indicated that MAGE-A1 expression can also be induced by other mechanisms [20]. In addition to its role as a putative component in aberrant DNA demethylation and transcriptional activation, BORIS may also participate in histone demethylation and chromatin remodelling [21, 22].

In the current study, we investigated the role of BORIS in the context of transcription factors Ets-1 and Sp1, known to be implicated in MAGE gene regulation, in the activation of MAGE-A1 expression. We found that BORIS can activate MAGE-A1, both at the endogenous transcript level and in reporter assays. Ectopic Sp1 expression partly abrogates this BORIS-induced activation, while ectopic Ets-1 lifts the repressive effect of Sp1. Interaction of both BORIS and Sp1 with the TATA binding protein (hTBP) is also established in our manuscript. Moreover, the impact of BORIS on the epigenetic signature associated with the MAGE-A1 promoter and its interaction with the transcription factors were analyzed.

Methods

Cell lines and drug treatment regimens

The cancer cell lines MDA-MB-468 and MCF-7 (breast adenocarcinoma) were cultured in DMEM (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (fetal calf serum; PAA Laboratories, Köln, Germany) and 2 mM L-glutamin (Invitrogen) under standard conditions (37°C, 10% CO2, humidified atmosphere). The micrometastatic BCM1 (breast cancer) cells [23, 24] were cultured at 37°C, 5% CO2 and 10% O2 in RPMI (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (PAA Laboratories), 2 mM L-glutamin (Invitrogen), 10 mg/mL Insulin-Transferrin-Selenium-A (Invitrogen), 50 ng/mL recombinant human epidermal growth factor, and 10 ng/mL human basic fibroblast growth factor (Miltenyl Biotec, Bergisch-Gladbach, Germany). Cell viability was determined.
by trypan blue staining. MCF-7 and BCM1 cells were stimulated by 5-aza-2’-deoxycitidine (5-aza-CdR, 1 μM, Sigma-Aldrich, Steinheim, Germany) for 72 h. 5-aza-CdR-treated or untreated cells were stimulated by Trichostatin A (TSA, 500 nM, Sigma-Aldrich) for 24 h after 48 hour incubation with or without 5-aza-CdR.

RT-PCR
For cloning of the transcription factors Ets-1, Sp1, and hTBP, total RNA was prepared using the RNaseasy® Mini Kit (Qiagen, Hilden, Germany) and performed according to the manufacturer’s description. Synthesis of cDNA was carried out using the First-strand cDNA synthesis kit and priming with the oligonucleotides dT (Fermentas, St. Leon-Rot, Germany). PCR amplification of cDNA was performed with primers specific for Ets-1: 5’-CAA AAA TGG TAC CAT GAA GGC GGC CGT GCT T-3’ and 5’-GAA TCA ACG CGC TCA GTC GGC ATC TGG-3’; Sp1: 5’- CCA AAA TGA ATT CAT GAG CGA CCA AGA TCA C-3’ and 5’-GAA TCA ACT CGA GTC AGA AGC CAT TGC CAC T-3’; full length, N-terminal and C-terminal hTBP: 5’-CCA AAA TGA ATT CAT GTA CCA GAA CAG C-3’, 5’-GAA TCA ACT CGA GTT-3’ and 5’-GAA TCA ACT CGA GTC AAG CCC ATC G-3’. The reaction was in a final volume of 20 μl containing PCR buffer (Qiagen), 200 μM of each dNTP (Roche Applied Science, Mannheim, Germany), 0.5 μM of each primer and 2.5 units of Pfu turbo hot start polymerase (Stratagene, Amsterdam, Netherlands). Template DNA was amplified in 35 cycles. The PCR products were separated on a 1% agarose gel.

Vector constructions
For transient transfections the MAGE-A1 promoter region fragment (-77/+183) containing the BORIS binding site downstream of the transcriptional start site was amplified in a PCR using the following primer pair: 5’-GTT CCC GCC AGG AAA CAT C-3’ and 5’-GCC CAG GCT GAG ACG TCT TCC-3’. After amplification the PCR product was cloned into a pCR2.1 TOPO vector (Invitrogen), digested with the restriction enzymes KpnI and Xhol and subcloned into the corresponding restriction sites of the pcGL2-Luciferase reporter plasmid (Promega). For the construction of the expression plasmids, we cloned cDNA of Ets-1 into KpnI and NolI, and of Sp1, full length, N-terminal and C-terminal hTBP into EcoRI and Xhol sites of the pcDNA3.1 vector (Invitrogen). The pBIG-HA BORIS plasmid containing the full-length BORIS sequence was described in [14].

To analyze protein-protein interactions, we amplified the sequences of Ets-1, Sp1, MBD1v1, MBD2b, hTBP-full length, hTBP-N and hTBP-C of pcDNA3.1 expression constructs and BORIS of pBIG-HA construct by primers containing the restriction sites SgfI and PmeI. Following specific primers were used for Ets-1: 5’-CAAA TGG CAT GAT CGA ATG AAC GGCG GCC GTC CAT G-3’ and 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; Sp1: 5’- CAA AAA TGG CAT GAC GAT CAG GCC GAT GGC GCC ATC TGG-3’ and 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’; 5’-GAA TCA ATG TTA AAC TCA CTC GTC GCC ATC TGG-3’. After PCR and gel purification, the fragments were inserted into pCR2.1 TOPO-vector (Invitrogen), cleaved by the restriction enzymes SgfI and PmeI, and cloned into pFN19A (HaloTag®7) T7 SP6 Flexi vector (Promega). All clones were verified by restriction digestion and DNA sequencing.

In vitro methylation of plasmid DNA
Twenty μg of reporter plasmids containing the MAGE-A1 promoter fragment were methylated by HpaII methylase (New England Biolabs, Schwalbach, Germany) for 4 h at 37°C in the presence of the co-factor SAM (S-Adenosyl methionine, New England Biolabs). The methylation efficiency of plasmid DNA was confirmed by restriction enzyme digestion with HpaII (New England Biolabs). A control digest was done using the isoschizomer MspI. After PCR and gel purification, the fragments were inserted into pCR2.1 TOPO-vector (Invitrogen), cleaved by the restriction enzymes SgfI and PmeI, and cloned into pFN19A (HaloTag®7) T7 SP6 Flexi vector (Promega). All clones were verified by restriction digestion and DNA sequencing.

Transient transfection and luciferase assay
MDA-MB-468, MCF-7 and BCM1 cells were transiently transfected with 0.5 μg of reporter plasmids (unmethylated or HpaII-methylated) and pcDNA3.1 expression plasmids up to 2 μg using FuGENE HD Reagent (Roche Applied Science, Mannheim, Germany) in a 6-well plate (BD Falcon, Heidelberg, Germany). For efficiency control 0.2 μg of a vector encoding for Renilla Luciferase (Promega, Mannheim, Germany) was co-transfected. Cells were
cultured for 48 h under standard conditions. Luciferase assays were performed using the Dual-Luciferase Reporter Assay System kit (Promega) according to the manufacturer’s protocol. Promoter-driven luciferase activity was measured on a 20/20° Luminometer Turner Biosystems (Promega) and normalized by the Renilla luciferase activity. Each transfection experiment was carried out in duplicate wells and repeated several times.

**Transient transfection and mRNA expression analyses**

To determine the mRNA expression of MAGE-A1 in MDA-MB-468, MCF-7 and BCM1 cells, transient transfections were performed using 5 μg expression plasmids and FuGENE HD Reagent (Roche Applied Science). After a 72 h transfection total RNA was isolated using the RNeasy™ Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA was converted into cDNA using the First Strand cDNA Synthesis kit (Applied Science) in a 6-well plate (BD Falcon). After a 72 hour transfection total RNA was isolated using the RNeasy™ Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA was converted into cDNA using the First Strand cDNA Synthesis kit and oligo(dt) primers (Fermentas). Two μl of cDNA (2 μg) were amplified in a 20-μl final volume containing PCR buffer (Qiagen), 200 μM of each dNTP (Roche Applied Science), 0.5 μM of each primer and 2.5 units of Taq DNA polymerase (Qiagen). The MAGE-A primer pairs for PCR have been previously described [6]. The reaction was run for 35 cycles on a Thermal Cycler (Flexigene, Techne, Stafordshire), and the PCR products were electrophoretically separated on a 1% agarose gel.

To degrade the BORIS mRNA and consequently, inhibit its protein expression, 1 μg expression plasmid containing the BORIS sequence and/or 1 μg plasmid containing the BORIS specific shRNA cassette and/or 1 μg control plasmid encoding for a scramble shRNA were transfected in BCM1 cells using FuGENE HD Reagent (Roche Applied Science) in a 6-well plate (BD Falcon). After a 48 or 72 h transfection total RNA was extracted and converted into cDNA. Two μl of cDNA (0.5 μg) were amplified in a quantitative real-time PCR.

**FACS (Fluorescence Activated Cell Sorting) analyses**

2×10^7 MCF-7 cells transfected with 5 μg pBIG-HA Boris expression plasmid and 10 μl XtremeGene HP (Roche Applied Science) were washed in 10 ml staining buffer (0.1% BSA, 0.1% sodium azide in PBS). Following incubation of the transfected and non-transfected cells with 50 μl FcR blocking reagent (Miltenyl Biotec) for 15 min at 4°C and washing in 10 ml staining buffer, the cells were fixed in 500 μl IC Fixation buffer (eBioscience, Frankfurt, Germany) in the dark for 20 min. The cells were washed twice in permeabilization buffer (eBioscience) and incubated with 4 μg of anti-Boris primary antibody or purified mouse IgGk isotype control antibody (BD Biosciences, Heidelberg, Germany) for 30 min at 4°C. After washing, the cells were incubated with 4 μg of FITC conjugated IgG/IgM goat anti-mouse secondary antibody (BD Biosciences) in the dark for 30 min at 4°C. The washed cells were filtered through a 30-μm CellTrics Filter (Partec, Münster, Germany). The filtered Boris-expressing cells were separated from non-transfected cells on the FACS Aria III device (BD Biosciences, Le Pont de Claix, France) using settings for maximum purity. Sorting was performed in staining buffer with an 85-μm nozzle, a 488-nm laser, a photomultiplier tube E, a 525-nm dichroic and a 543/22-nm excitation filter. Sorted cells were collected in DMEM containing 10% FCS. Usually, approximately 4.5% of transfected cells could be separated from non-transfected cells. Different approaches of transfected and non-transfected cells were performed: non-labeled, isotype control antibody and anti-Boris primary antibody.

**DNA methylation analysis by sodium bisulfite sequencing**

For the sodium bisulfite conversion the EpiTect bisulfite kit (Qiagen) was used according to a modified protocol. One μg of genomic DNA supplemented with 35 μl DNA Protect buffer and 85 μl bisulfite mix were alternately denatured at 99°C and incubated at 60°C for 5, 25, 5, 85, 5 and 175 min. Following purification and concentration of the sodium bisulfite-treated DNA on an EpiTect column (Qiagen), 1 μl of the modified DNA was amplified with primers specific for MAGE-A1 and -A2 promoter fragments [6]. The PCR products were purified using the DNA Clean & Concentrator-5 kit (Zymo Research, Greiburg, Germany) and sequenced using the Big Dye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) on an automated Genetic Analyzer 3130 (Applied Biosystems).

**Chromatin immunoprecipitation (ChIP) assay**

Exponentially growing MCF-7 cells stimulated by 5-aza-CdR (Sigma-Aldrich) and/or TSA (Sigma-Aldrich) as well as cells transfected by BORIS expression plasmid were used in ChIP experiments. The Magna ChIP™ G Chromatin Immunoprecipitation Kit (Millipore, Schwalbach, Germany) was carried out according to the manufacturer's recommendations. Briefly, cells were fixed in 1% formaldehyde in minimal medium for 10 min at room temperature (RT) before being washed, scraped, and pelleted in ice-cold PBS. Cells were lysed with a hypotonic lysis buffer supplemented with a protease inhibitor cocktail for 15 min on ice, and nuclei were pelleted by centrifugation for 5 min, 2900 rpm at 4°C. The nuclei pellet was sheared in 500 μl nuclear lysis buffer supplemented with a protease inhibitor cocktail by sonication at 25% power for 4 min on ice (Sonicator UP50H; Dr. Hielser GmbH, Teltow, Germany) to chromatin fragment lengths of 200 to 1000 bp. Aliquots of whole-cell lysates were saved as input DNA. The sonicated lysates were immunoprecipitated using 3 μg of either the control antibody IgG (Abcam, Cambridge, United Kingdom)
or antibodies against acetylated histones H3 (H3K9ac) (Upstate) and H4 (H4K8ac) (Abcam), and methylated histones H3K4me, H3K4me2, H3K9me, H3K9me3, H4K20me, H4K20me2 and H4K20me3 (Upstate). Twenty μl magnetic beads (protein G, Millipore) were added to each reaction and incubated overnight at 4°C. After washing, the immunoprecipitants were recovered and incubated with proteinase K (Millipore) for 2 hours. The DNA fragments were purified on columns (Millipore) and eluted by 50 μl of elution buffer.

**Quantitative real-time PCR**

Quantitative real-time PCR analysis was performed using the QuantiTect SYBR Green PCR kit system (Thermo Fisher, Schwerte, Germany) on a Realplex® System Mastercycler Eppgradient S (Eppendorf, Hamburg, Germany). Each reaction contained 2 μl cDNA or purified immunoprecipitated DNA fragments, 5 μl SYBR-Green PCR master mix and 4 pmol primer sets in a final volume of 10 μl. The DNA was amplified by the primer pairs specific for BORIS (5'-CTC AGG TGA GAA GCC TTA CG-3' and 5'-TGA TGG TGG CAC AAT GGG-3'), MAGE-A1 (5'- GGC CGA AGG AAC CTG ACC -3' and 5'-GTC CTC TGG GTT GGC CTG-3'), β-Actin (5'-CCA ACC GCC AGA AGA TGA -3' and 5'-CCA GAG GGC TAC AGG GAT AG-3') and RPLP0 (housekeeping gene, ChIP , 5'-TTA TTG TGC TGA GCT CGC CAG-3' and 5'-CTC TGA GCT GCT GCC ACC TG-3'). The following PCR cycling conditions were used: 95°C for 15 s, 58°C or 60°C for 30 s, and 72°C for 30 s, for 45 cycles. After amplification the specificity of PCR products was determined by melting curve analyses. For quantification a serial dilution of genomic DNA was generated and served as internal standard in each run. For the amplified immunoprecipitated DNA, the background of non-specific IgG immunoprecipitation was subtracted from the calculated ratio between the data derived from the histone-specific immunoprecipitation and input DNA. Each sample was thermocycled in duplicate, and all experiments were repeated at least three times.

To analyze the expression patterns of BORIS isoforms in basal and BORIS-transfected MCF-7 and BCM1 cells, quantitative real-time PCR was performed as previously described [17]. BORIS isoforms were divided into six subfamilies, sf1 to sf6, based on their 39 sequences [17]. The Taqman probe sf1 was designed against sequences between exon 9 and 10 of the BORIS B0 and detects BORIS isoforms B0, B1, A1, A2, A3, and C1 (Additional file 1: Table S1). The absolute quantification approach was applied to estimate the actual number of BORIS transcripts detected by the sf1 probe. The Taqman probe sf2 detects at least two BORIS isoforms, A4 and C2 that produce the same protein but are expressed from two alternative promoters, A and C, respectively. The Taqman probe sf3 probe detects five isoforms: A5, A6 B4, B5, and C6. The Taqman probe sf4 was designed to detect at least six BORIS isoforms: C3, B2, B3, C4, C5, and C8. The B1 isoform has a unique C-terminus and 3'UTR that were used to design the sf5 probe. The sf6 probe detects four BORIS isoforms: B6, B7, C7, and C9 [17].

**Expression of recombinant protein**

For protein expression and purification the EnPresso™ Tablet Cultivation Set (BioSilta, Oulu, Finland) and HaloTag® Protein Purification System (Promega) were used, respectively. To induce protein expression, a transformed culture of KRX competent cells (Promega) at an optical density of 9-13 at 600 nm was supplemented with a “booster solution” (EnZ Im and 0.05% rhamnose). After centrifugation for 10 min at 5600 rpm and 4°C, the cell pellet was resuspended in HaloTag® Protein Purification buffer (50 mM HEPES, 150 mM NaCl, 1 mM DTT, 0.005% IGEPAL CA-630; Promega), 10 mg/ml lysozyme (Sigma-Aldrich) and RQ1 RNase free DNase (Promega) and disrupted by sonication at 60% power for 45 s on ice (Sonicator UP50H; Dr. Hielser GmbH, Teltow, Germany). The proteins were purified from the sonicated cell lysates according to the manufacturer’s recommendations (Promega). Briefly, lysates were incubated with HaloLink™ resin, followed by washing with HaloTag® Protein Purification buffer and cleavage with TEV Protease Cleavage Solution (HaloTag® Protein Purification buffer supplemented with 1/16 volume TEV protease) on a rotator (NeoLab, Heidelberg, Germany) for 1 h at RT. After centrifugation 50 μl of 50% HisLink™ resin was added and incubated on the rotator for 20 min at RT. The supernatant contained the recombinant proteins.

**Pull down assay**

Pull down assay was carried out according to the manufacturer’s recommendations for HaloLink™ resins (Promega). The “bait” HaloTag fusion proteins were prepared by incubating 1 μg FN19A (HaloTag®7) T7 SP6 Flexi vector (Promega) with in vitro TNT® Quick-coupled Transcription/Translation System (Promega) containing 40 μl TNT Quick Master mix and 1 mM methionine at 30°C for 90 min. The “prey” proteins were prepared by incubating 1 μg pcDNA3.1 constructs with TNT® Quick-coupled Transcription/Translation System (Promega) and 1000 Ci/mol labeled [35S]-methionine (Hartmann Analytic, Braunschweig, Germany) at 30°C for 90 min. For the assay 20 μl of each bait and prey proteins were mixed and incubated for 1 h at RT on a shaker. As a negative control 20 μl TNT Master mix were used instead of using the
“bait” protein. The HaloLink™ resin was prepared by washing in binding buffer (100 mM Tris (pH 7.6), 150 mM NaCl and 0.05% IGPAL-630) three times. Twenty μl of bait-prey complex were added to the HaloLink™ resin resuspended in 100 μl binding buffer. After incubation on a rotator for 90 min at 4°C, the complex was centrifuged and washed three times in wash buffer (100 mM Tris pH 7.6, 150 mM NaCl, 1 mg/ml BSA and 0.05% IGPAL-630). The bound proteins were separated on a 12% SDS polyacrylamide gel.

Statistical analyses
The statistical analyses were performed using the SPSS software package, version 18.0 (SPSS Inc. Chicago, IL). Statistical difference of mRNA expressions was calculated using ANOVA with Dunnett test for all pairwise comparisons that correct for experiment-wise error rate. Missing data were handled by pairwise deletion. A p-value ≤0.05 was considered as statistically significant. All p-values are two-sided.

Ethics statement
In the present manuscript, the research does not involve human subjects, human material, or human data, or used regulated vertebrates or invertebrates

Results
BORIS stimulates MAGE-A1 mRNA expression in MCF-7 and BCM1 cells
We previously demonstrated that the demethylating agent 5-aza-CdR and the histone deacetylase inhibitor TSA synergistically upregulate MAGE-A1 expression in cell lines derived from different cancer types [6]. Moreover, Vatolin et al. reported that conditionally expressed BORIS induces expression of a series of CTA genes, including MAGE-A1 gene [14], but converse data have also been reported demonstrating that stable expression of BORIS in melanoma cell lines did not induce expression of MAGE-A1 [20]. In order to examine whether BORIS is actually able to activate the MAGE-A1 promoter and to which extent, we compared its influence with the stimulatory effect of 5-aza-CdR and/or TSA on MAGE-A1 transcription in cancer cell line settings. For our current investigations, we chose 3 breast cancer cell lines: MDA-MB-468, MCF-7 and BCM1 because of their different levels of MAGE-A1 and BORIS transcripts. As shown in Table 1 and measured by quantitative real-time PCR, MDA-MB-468 cells express relatively high levels of MAGE-A1 [2^(ΔCt) 19.33] and BORIS mRNA [2^(ΔCt) 48.78], whereas MCF-7 cells do not (or negligibly) express MAGE-A1 mRNA [2^(ΔCt) 2.00] and express low levels of BORIS [2^(ΔCt) 6.92 with a high standard deviation]. In the micrometastatic cell line BCM1, the expression of both genes is opposite: no levels of MAGE-A1 [2^(ΔCt) 1.07] and high levels of BORIS [2^(ΔCt) 24.39]. We transiently transfected expression plasmid encoding BORIS into both cell lines, with negligible transcript levels of MAGE-A1, and quantified endogenous MAGE-A1 mRNA by RT (reverse transcription)-PCR and gel electrophoresis. As depicted in Figure 1, BORIS was able to stimulate or induce the expression of MAGE-A1 in MCF-7 cells (Figure 1A) and BCM1 (Figure 1B) cells. In both cell lines, the BORIS-mediated stimulation was much weaker than the stimulatory effect by both agents (5-aza-CdR and/or TSA, Figure 1). Performing real-time PCR, we found that 5-aza-CdR (p = 0.0001), TSA (p = 0.001), 5-aza-CdR plus TSA (p = 0.0001) and BORIS (p = 0.04) stimulated the RNA expression 30-, 18-, 60- and 7-fold, respectively, in MCF-7 cells (Figure 1C). This ostensibly weaker activation by transfected BORIS may be partly due to the fact that transfection efficiency is usually much lower and about 10% (as deduced from FACS analyses and shown later), but 5-aza-CdR and TSA treatment can affect 100% of cells taken into experiment.

Knock-down of BORIS mRNA reduces the transcript levels of MAGE-A1
To further evaluate the stimulatory effect of BORIS on MAGE-A1 gene expression, we carried out knock-down experiments in MDA-MB-468 and MCF-7 cells. First, we determined the expression levels of BORIS in MDA-MB-468, MCF-7 and BCM1 cells by RT-PCR and gel electrophoresis. As expected, we found a similar expression profile of BORIS mRNA (Figure 2) to that detected by quantitative real-time PCR (Table 1). However, gel electrophoresis and quantitative real time showed no and low expression levels of BORIS in MCF-7 cells, respectively, but the tendency was similar. The additional stimulation with 5-aza-CdR showed that induction of BORIS expression may occur by DNA demethylation (Figure 2). We knocked down the high expression of endogenous BORIS in MDA-MB-468 cells by a BORIS specific shRNA cassette. The transfection with a plasmid encoding for a scramble shRNA served as a control. At 48 or 72 hour post-transfection, we quantified the changes in the BORIS

### Table 1 Relative expression levels of MAGE-A1 and BORIS mRNA in breast cancer cell lines as measured by quantitative real-time PCR

| Cell lines     | MAGE-A1  | BORIS     |
|----------------|----------|-----------|
| MDA-MB-468     | 19.33 ± 3.84 (high) | 48.78 ± 3.38 (high) |
| MCF-7          | 2.00 ± 0.87 (no)    | 6.92 ± 3.86 (low)   |
| BCM1           | 1.07 ± 0.35 (no)    | 24.39 ± 3.34 (high) |

The relative mRNA expression levels were evaluated by the ΔCt method as follows: ΔCt = Ct value of reference RPLPO - Ct value of mRNA of interest. The relative expression levels of the mRNA of interest corresponded to the 2^(ΔCt)×1000 value.
and MAGE-A1 mRNA levels by quantitative real-time PCR and RT-PCR/gel electrophoresis. As measured by real-time PCR, BORIS-specific shRNA reduced the endogenous BORIS mRNA expression from 100% down to 20% in basal MDA-MB-468 cells (p = 0.0001) and, documenting more the specificity of the experiment, from 75% down to 40% in MDA-MB-468 cells transfected with the control plasmid encoding for scramble shRNA (Figure 3A, p = 0.008). As shown by quantitative real-time PCR (Figure 3B, p < 0.05) and on an agarose gel (Figure 3C), the BORIS-specific shRNA (with and without scramble shRNA) downregulated the basal endogenous MAGE-A1 expression approximately 30%. We also carried out these knock-down experiments in MCF-7 cells that were additionally transfected with an expression plasmid encoding for BORIS. Therefore, we co-transfected MCF-7 cells with an expression plasmid encoding for BORIS, to upregulate MAGE-A1 expression in this cell line. BORIS-specific shRNA reduced the BORIS mRNA expression nearly completely in presence and absence of scramble shRNA (Figure 3D, p = 0.0001). Likewise, the downregulation of MAGE-A1 expression by BORIS-specific shRNA was more prominent in MCF-7 cells than in MDA-MB-468 cells. As measured by quantitative real time PCR, BORIS-specific shRNA reduced the MAGE-A1 expression down to 10% in presence and absence of scramble shRNA (Figure 3E, p = 0.0001). This stronger downregulation of BORIS and MAGE-A1 in MCF-7 cells is caused by the overexpression of BORIS in these cells, whereas the analyses in MDA-MB-468 were carried with endogenous BORIS.

These results show that changes in the BORIS transcript levels are associated with those of MAGE-A1 expression and corroborate that BORIS is involved in the activation of MAGE-A1 gene expression.

BORIS affects the DNA methylation pattern of MAGE-A1 gene

Promoter hypermethylation is responsible for the restricted expression of the tumor-associated MAGE-A antigens. It
was reported that DNA demethylation of the Ets-1 binding sites of the MAGE-A1 promoter is sufficient to activate gene expression [5]. In addition, the transcriptional start site located in the region between -30 and +30, and responsible for basal activity of the MAGE-A1 promoter, should be demethylated for the induction of MAGE-A expression [25]. Previously, we investigated the influence of the DNA demethylation agent 5-aza-CdR together with the histone deacetylase inhibitor TSA on the mRNA expression of MAGE-A1 gene and the other family members (MAGE-A2, -A3 and -A12) in different cell lines. Moreover, we assessed the methylation status of the MAGE-A promoters by sodium bisulfite mapping before and after stimulation with the demethylating agent 5-aza-CdR and/or TSA. While the methylation patterns clearly correlated with the basal MAGE RNA transcript levels, up-regulation of MAGE-A expression mediated by 5-aza-CdR resulted in a reduction in promoter methylation ranging between 1% and 19%. Although TSA was able to synergistically enhance 5-aza-CdR-mediated MAGE-A transcription, we could not observe further DNA demethylation with both substances (5-aza-CdR + TSA) together [6]. This heterogeneous DNA methylation pattern could be caused by the heterogeneous and random spreading of the demethylating agent in the cells, and the insensitivity of some cells to these agents.

Figure 3 BORIS-specific shRNA knocks down BORIS and decreases MAGE-A1 gene expression. MDA-MB-468 (A, B, C) and MCF-7 (D, E) cells were transiently transfected with expression plasmid containing BORIS-specific shRNA and control plasmid encoding for a scramble shRNA. In contrast to MDA-MB-468 cells with their high levels of endogenous MAGE-A1 and BORIS mRNA levels, MCF-7 cells showing no expression of MAGE-A1 were additionally cotransfected with the expression plasmid containing the BORIS sequence. After a 48 hour transfection, mRNA levels were measured by PCR. Changes in mRNA expression levels of BORIS (A) and MAGE-A1 (B) by quantitative real-time PCR and MAGE-A1 by gel electrophoresis (C) in MDA-MB-468 cells. Real-time PCR derived changes in mRNA expression levels of BORIS (D) and MAGE-A1 (E) in MCF-7 cells. The significant p-values are shown.
In respect to the inducing effect of BORIS on MAGE-A1 mRNA expression, it was of interest to examine the influence of BORIS on methylation pattern of the MAGE-A1 promoter. In the present study, we compared the DNA methylation patterns of the promoter in MCF-7 cells transfected with the expression plasmid encoding for BORIS to the pattern in non-transfected and untreated cells. For these experiments, we chose, therefore, MCF-7 cells, because they do not express MAGE-A1 mRNA (Table 1). Based on the usually low transfection efficiency we sorted the transfected MCF-7 cells from untransfected cells by FACS and observed a transfection efficiency of about 10%. Subsequently, sodium bisulfite mapping showed a demethylation of the MAGE-A1 promoter of approximately 56% (range from 44 to 69%) in the sorted BORIS-transfected cells, compared with the sorted non-transfected and untreated MCF-7 cells. As shown by two examples of the supplementary Additional file 2: Figure S1, BORIS demethylated the binding sites for Ets-1, Sp1 and BORIS which are essential for the activation of MAGE-A1.

### Histone modifications at the promoter of MAGE-A1

Besides DNA methylation, histone modifications also have an impact on promoter activity. In general, acetylation of N-terminal histone tails is a dominant signal for active chromatin facilitating the binding of components of the basal transcription machinery and transcription factors [26]. Histone methylation can be either an active or repressive signal. Mono-, di- and trimethylation of H3K4 are involved in gene expression [9]. The monomethyllations of H3K9 and H4K20 are linked to gene activation, whereas trimethylations of these histones at lysine residues are linked to repression [27].

Since BORIS may demethylate the MAGE-A1 promoter, we also analyzed its impact on the modifications of histones bound at the MAGE-A1 promoters. To investigate the changes in the histone signature of MAGE-A1 promoter, it was compared in basal MCF-7 cells (no expression of MAGE-A1, Table 1) to the signature in MCF-7 cells stimulated by 5-aza-CdR with/without TSA or transfected with the expression plasmid encoding for BORIS. For these analyses we used antibodies specific for acetylated histones H3K9 and H4K8, and for methylated histones H3K4, H3K9 and H4K20. We performed immunoblot analyses and documented specific recognition of histone modifications by these specific antibodies. The histone modifications could not be determined in the micrometastatic BCM1 cells because of their slow cell growth and high cell death caused by 5-aza-CdR and TSA. Upon treatment of MCF-7 cells with TSA, an enrichment of H3K9ac could be observed, indicating the function of TSA as histone deacetylase inhibitor (p = 0.001). While DNA demethylation by 5-aza-CdR had no or a minor effect on the histone modifications, 5-aza-CdR and TSA were able to enrich H3K9ac, H4K8ac, H3K9me, and H3K4me2 (p = 0.0001). Based on their low levels, the relative changes in the histone modifications of H3K4me3, H4K20me, H4K20me2 and H4K20me3 could not be evaluated, but did not seem to be significant (Figure 4). Due to the nature of the experimental procedures of ChIP, we could not sort transfected cells from untransfected cells by FACS analyses.
Therefore, the predominant occurrence of untransfected cells in the transfection assay (10% of transfection efficiency) may be the reason, that we could not observe any alterations in the histone modifications mediated by transfected BORIS (Figure 4).

**Differential effects of transcription factors BORIS, Sp1 and Ets-1 in the regulation of MAGE-A1 expression**

In order to functionally investigate the impact of BORIS on promoter settings, we examined the influence of BORIS on the activity of the methylated MAGE-A1 promoter in the context of transcription factors Ets-1 and Sp1. We transiently co-transfected methylated reporter plasmids pGL2/MAGE-A1 (-77/+183) containing the BORIS binding site located downstream of the start site (Figure 5A), and expression plasmids encoding for BORIS, Ets-1 or Sp1 into BCM1 cells. As expected, aberrantly expressed transcription factors Ets-1 and Sp1 had no effect on methylated MAGE-A1 [11]. However, transfected BORIS was able to activate the methylated promoter in these cells (p = 0.0001). Overexpression of Ets-1 could not further upregulate the promoter activity mediated by BORIS, as shown by several repetitions. Surprisingly, co-transfection with an expression plasmid encoding for Sp1 partly repressed the stimulatory effect mediated by BORIS (p = 0.001), whereas the addition of expression plasmid encoding for Ets-1 abrogated this repression (Figure 5B).

To verify the repressive effect of Sp1 on the BORIS-activated MAGE-A1 promoter, we transiently transfected the expression plasmids into MCF-7 and BCM1 cells, and analyzed the endogenous MAGE-A1 mRNA level by gel electrophoresis. Ectopic expression of BORIS could induce the mRNA expression of MAGE-A1 in both cell lines (Figure 5C). This upregulation could be slightly increased by the co-expression of Ets-1. In contrast, exogenous Sp1 reversed the stimulatory effect mediated by BORIS on MAGE-A1 mRNA transcription. We repeated the experiments.

---

**Figure 5** MAGE-A1 promoter activity in basal and transfected cancer cells. Schematic view of the MAGE-A1 promoter fragment (-81/-185). The binding sites for Ets-1, Sp1 and basal transcription complex are indicated by grey boxes. The start site is indicated by an arrow. The vertical lines with the numbers mark the cytosine in the CpG dinucleotides (A). Luciferase activity of the HpaII-methylated plasmid containing the MAGE-A1 promoter fragment (-77/+183) in BCM1 cells which were transiently co-transfected with expression plasmids encoding for BORIS, Ets-1 and Sp1. The basal MAGE-A1 promoter activity was set to 100%. The activities derived from the reference plasmid encoding for the Renilla Luciferase were used to normalize the variability in transfection efficiency. The significant p-values are shown (B). Endogenous mRNA expression of MAGE-A1 in MCF-7 and BCM1 cells basal or transfected with expression plasmids encoding for BORIS, Ets-1 and Sp1 as determined by RT-PCR and gel electrophoresis. The housekeeping gene β-Actin was selected as an internal control due to the lack of influence of any stimulation involved (C).
on transcription of MAGE-A1 several times with similar results (Figure 5C). These findings support our data obtained from the reporter luciferase activity measurements (Figure 5B) and indicate a differential regulation of the MAGE-A1 by BORIS and Sp1.

To compare the transfection efficiency and assess if similar amounts of the different expression plasmids entered BMC1 and MCF-7 cells, we performed real-time PCR using primers that specifically bind to the expression plasmids and the inserted genes (BORIS, Ets-1 and Sp1). We found a CT value of 27.3 (STD 0.3) for BORIS, 27.3 (STD 0.2) for Ets-1, 27.8 (STD 0.2) for Sp1, indicating a similar inclusion of the expression plasmids.

Ectopic BORIS expression upregulates its alternatively spliced transcripts from its own genomic locus

The differential regulation of MAGE-A1 gene expression could be explained by a separate site in MAGE-A1 promoter that could be recognized by a BORIS alternatively spliced isoform with different sequence specificity. For this reason, we compared mRNA patterns of alternatively spliced BORIS isoforms in basal MCF-7 and BCM1 cells with analogous cells transfected with BORIS (the first cloned, original form B0). As we recently described [17], BORIS isoforms could not be specifically discriminated by quantitative RT-PCR because most isoforms share sequence similarities, making it impossible to design primers and probes that would detect each BORIS isoform as a separate species. Therefore, we operationally divided the 23 isoforms into six subfamilies (sf1 to sf6) based on their unique 3’ terminal sequences, which were used to design 6 Taqman probes for quantitative real-time PCR [17]. With the exception of sf1, which detects the original BORIS form (B0) that was transfected into the cell lines, we measured the relative units of BORIS isoforms sf2 to sf6 in basal and BORIS-transfected MCF-7 and BCM1 cells. As shown in Figure 6, BORIS stimulated substantially its isoforms sf3 to sf6 in MCF-7 cells which do not express endogenous BORIS (Figure 6A, p = 0.0001), whereas BORIS only stimulated weakly sf2 and sf3 in BCM1 cells which express high levels of endogenous BORIS (Figure 6B).

Interaction of transcription factors BORIS and Sp1 with the TATA binding protein

In our recent publication, we have shown the cooperative and competitive interplay of transcription factors (Ets-1, Sp1) and epigenetic factors (BORIS, MBD1, MBD2a) to activate or repress the MAGE-A1 promoter by transient transfection assays [11]. To determine if these proteins, together with BORIS, can form secondary complexes with each other in the absence of DNA and to understand better the mechanism underlying the regulation of MAGE-A1 expression, we carried out in vitro protein-protein interaction assays. Each of the proteins was either a resin-bound “bait” fusion protein or a [35S]-L-methionine labeled “prey” protein. As shown by the separation of the bound proteins on polyacrylamide gels and previously reported [28,29], the transcription factor Sp1 efficiently interacted with Ets-1 and the amino-terminus of the human TATA binding protein (hTBP), the general transcription factor of the basal transcription complex. We show for the first time, that Sp1 also interacted with BORIS and MBD1v1, which up- and downregulate MAGE-A1 promoter activity, respectively, but this protein-protein interaction was much weaker than its interaction with Ets-1 and hTBP amino-terminus. Conversely, hTBP interacted with MBD2b, BORIS, Ets-1 and Sp1 (Figure 7A). For the interaction with MBD2b and BORIS the evolutionarily conserved carboxyl (C) terminus of hTBP was necessary and sufficient. At present, it is unclear whether these interactions with hTBP play a functional role in the competitive transcriptional regulation of Sp1 and BORIS. However, this observation is supported by our ChIP-seq data on several cancer cell lines – BORIS sites are frequently overlapped with hTBP [17]. For a better overview,
Discussion
In the current study devoted mainly to understanding the transcriptional regulation of MAGE-A1, we detected that ectopically expressed BORIS was able to induce MAGE-A1 promoter activity in MCF-7 cells and micro-metastatic BCM1 cells. This activation by BORIS was associated with DNA demethylation of the MAGE-A1 promoter. It is of interest that MAGE-A1 activation by BORIS may vary depending on cell line but the strongest upregulation occurs when there is already low expression level of MAGE-A1. If the expression is completely shut down as in normal primary cells, activation is also observed but at a very low level and, likely, in a fraction of cells. These data suggest that the epigenetic landscape of cells is different and their responsiveness to ectopic transcription factors is also different. In our present study, we describe the complex interplay of general transcription and epigenetic factors in MAGE-A1 regulation. Exogenous Sp1 partly repressed the induction of MAGE-A1 gene expression mediated by BORIS. Ets-1 could not further upregulate the BORIS-mediated promoter activity, but Ets-1 abrogated the Sp1-mediated repression in reporter assays. As the two Ets-1 sites overlap the Sp1 site, it appears to be rather simple to postulate 1) that the opposite effects of those two factors are due to their interference on the promoter, and 2) Ets-1 effects are stronger probably because there are two Ets-1 sites compared to one Sp1 site in the MAGE-A1 promoter. The BORIS site is located about 150 bp downstream to the Sp1 site, in the first exon of MAGE-A1.

As Sp1 and BORIS have independent target sites around the start site of the MAGE-A1 promoter, the opposite effects of those two factors need to be mechanistically explained. Thus, the competitive interplay between BORIS and Sp1 does not seem to be caused by alternation of the DNA binding of both factors. However, the physical protein-protein interaction between BORIS and SP1, which we observed and was also recently reported [30], might diminish the BORIS-mediated activation of MAGE-A1.

The repressive effect by Sp1 could also be favored by its additional interaction with the epigenetic factor MBD1v1. It is still unclear whether MBD1v1 exerts its repressive effect by interaction with Sp1 at the Sp1 binding site of the promoter or by preventing the binding of Sp1 to its motif. Our preliminary data suggest that the third cysteine-rich CXXC domain of MBD1v1 is involved in this interaction, because the splice variant MBD1v3, which lacks this domain, did not bind to Sp1. The ability of MBD1v1 to repress unmethylated promoters also depends on this third CXXC domain [12]. In this regard, our recent binding analyses of EMSA showed that MBD1v1 does not only bind to methylated, but also to unmethylated MAGE-A promoters and is able to repress unmethylated MAGE-A promoters [11]. This in vitro ability is also supported by a previously published study demonstrating a methylation-independent repression by MBD1v1 on another promoter [31]. Our data are of note, because co-transfection of Ets-1 or Sp1 did not lead to an abrogation of MBD1v1-mediated repression [11]. In respect to the potential role of MBD1v1 as a repressor of unmethylated MAGE-A promoters and to the mechanisms underlying the transcriptional repression, we investigated whether

Figure 7B schematically summarizes the protein-protein interactions.
MBD1v1 can also interact with Ets-1. Due to problems in the production of recombinant Ets-1 protein, we could not determine if Ets-1 can form a secondary complex with MBD1v1.

How does the binding of Sp1 partly abrogate BORIS activation? Currently, we can suggest either direct interaction of BORIS with Sp1 generating a DNA kink that diminishes transcription, or a separate site in MAGE-A1 promoter that could be recognized by a BORIS alternatively spliced isoform with different sequence specificity. That site might overlap with the Sp1 site and thus directly interfere with the Sp1 transcription factor. Ets-1 could stabilize BORIS isoform binding preventing Sp1 to act at this site. We show here that BORIS can activate transcription of its own locus. However, the strength of this activation depends on the cell line and likely on other transcription factors present in a particular cell type. More research is required to clarify this phenomenon.

Both BORIS and Sp1 are capable of binding to different domains of hTBP, the general transcription factor of the basal transcription machinery, which forms a preinitiation complex with RNA polymerase II to start mRNA transcription. Our data are in line with previously published data showing that Sp1 interacts with the N-terminus of hTBP [32]. In contrast, the interaction between BORIS and hTBP takes place with the C-terminal evolutionarily conserved domain of hTBP, which has been shown to interact with several other transcription factors [32,33]. One could envisage that the MAGE-A1 promoter activity mediated by BORIS might be based on its direct interaction with the general transcription factor hTBP. However, to support this hypothesis, further experiments, such as luciferase assays, are to be assessed.

Furthermore, we demonstrate for the first time that the epigenetic factor MB2a also interacts with the C-terminal domain of hTBP. In our recent study, we reported that although MB2a had no binding activity to MAGE-A1 promoters in EMSA and ChIP assays, transfected MB2a could stimulate luciferase activity of the unmethylated reporter plasmids containing the MAGE-A promoter fragments in a variety of cancer cell lines [11]. Fujita et al. explained the lack of binding activity of MB2a and its activating effect for cAMP-responsive genes by the interaction of MB2a with the RNA helicase A. They depicted a hypothetical model illustrating MB2a as a factor in the transcriptional co-activator complex which is associated with RNA polymerase II [13]. We complement this model and show that MB2 may interact with hTBP. This link with the basal transcription machinery could explain how MB2a promotes MAGE-A transcription.

Functional studies reported that BORIS is neither necessary nor sufficient for DNA hypomethylation and activation of CTA genes in melanoma and ovarian cell lines, and additional factors are likely required for CTA antigen expression [20,34]. Those data are in contrast to our previous data, which showed that aberrantly expressed BORIS is responsible for DNA demethylation and subsequent activation of most CTAs, including MAGE-A1, in carcinomas [14]. Our present observations support the hypothesis that BORIS may demethylate the MAGE-A1 promoter, upregulate the promoter activity and induce mRNA expression. In particular, BORIS seems to participate in DNA demethylation of the binding sites for the transcription factor Ets-1 and the transcriptional start site for the basal transcription complex. These target sites essential for the activation of MAGE-A1 are methylated in MAGE-A-negative cells.

Covalent modifications associated with histone tails are also involved in regulation of gene expression. The histone code dictates the recruitment of specific factors that in turn define the formation of open or closed chromatin structures [35,36]. We could endorse the function of TSA as histone deacetylase inhibitor, because TSA was able to enrich acetylated H3K9. Our investigations also showed that both agents, 5-aza-CdR and TSA, were necessary to launch distinct histone modifications at the MAGE-A1 promoter. However, we found no effect of BORIS on the histone code. This could be explained by the low transfection efficiency of 10%. Recently, Bhan et al. showed that BORIS is able to change the histone code at the promoters of the MAGE-A members MAGE-A2, -A3 and -A4. In bronchial cancer cells, BORIS induction resulted in increased amounts of BORIS and activating histone modifications at these promoters along with a corresponding increase in CTA expression. Whereas BORIS binding at these promoters correlated with enrichment of activating modifications, absence of BORIS was associated with enrichment of repressive histone codes [37]. Moreover, it was reported that BORIS helps to recruit histone (H3K4) methyltransferase, SET1A, onto the promoters of myc and BRCA1 to promote a permissive histone modification status [21].

Conclusions
In conclusion our data show that BORIS may demethylate and activate the MAGE-A1 promoter. The induction of the MAGE-A1 mRNA expression could be provoked by the interaction between BORIS and hTBP. Sp1 could partly repress the BORIS-mediated stimulatory effect by its direct interaction with BORIS and MBD1v1. Moreover, the secondary complex formation of MB2 with hTBP may also play a role in the activation of MAGE-A transcription. However, more experiments have to be done to clarify the interplay of these factors in the regulation of MAGE-A genes expression.

Schwarzenbach et al. BMC Cancer 2014, 14:796
http://www.biomedcentral.com/1471-2407/14/796
Additional files

**Additional file 1: Table S1.** The primers and the Taqman probes used in quantitative real-time RT-PCR.

**Additional file 2: Figure S1.** Bisulfite-treated MAGE-A1 promoter sequence in sorted non-transfected and sorted BORIS-transfected MCF-7 cells.

Abbreviations
BORIS: Brother of the Regulator of Imprinted Sites; ChIP: Chromatin immunoprecipitation assay; CTA: Cancer-testis antigens; fetal calf serum: FCS; MAGE-A: Melanoma-associated antigen A; MD2s: Methyl-CpG binding proteins; hTBP: Human TATA binding protein; RT: Reverse transcription; TSA: Trichostatin A; 5-aza-CdR: aza-2´-deoxycitidine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
HS, VL, DL conceived and designed the experiments. CE, BS, JT performed the experiments. HS, VL, DL discussed the results and their biological relevance. HS wrote the manuscript. KP, VL, DL corrected the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We thank Mrs. Melanie Lachmann, Constanze Sigregel, Regine Thiel and the Core Unit FACS-Sorting of the University Hospital Hamburg-Eppendorf for the helpful assistance to carry out flow cytometry.

Grant support
The study was supported by the Stiftung für Pathochemie and Molekular Diagnostik, Bonn, Germany, and the Wilhelm Sanders Stiftung, München, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author details
1. Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
2. Laboratory of Immunogenetics, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland, USA.

Received: 21 July 2014 Accepted: 23 October 2014 Published: 3 November 2014

References
1. Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100(11):2014–2021.
2. De Planer F, Arden K, Traversari C, Gafonio J, Skoletzka JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Luquin C, Brasseur R, Chomez P, De Backer O, Caveness W, Boon T: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40(3):360–369.
3. Jungbluth AA, Busam KJ, Kolb D, Ivensen K, Coplan K, Chen YT, Spagnoli GC, Old LJ: Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000, 85(4):460–465.
4. James SR, Link PA, Karpf AR: Epigenetic regulation of X-linked cancer/germline antigens by DNMT1 and DNMT3b. Oncogene 2006, 25(52):6975–6985.
5. De Smet C, Courtin S, Farooq I, Luquin C, Skoletzka JP, De Backer O, Boon T: Involvement of two Ets binding sites in the transcriptional regulation of the MAGE1 gene. Immunogenetics 1995, 42(4):282–290.
6. Wischnewski F, Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4(5):339–349.
7. Zheng YG, Wu J, Chen Z, Goodman M: Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 2008, 28(5):645–687.
8. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21(1):103–107.
9. Hashimoto H, Vertino PM, Cheng X: Molecular coupling of DNA methylation and histone methylation. Epigenomics 2010, 2(5):657–669.
10. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31(2):89–97.
11. Wischnewski F, Friese O, Pantel K, Schwarzenbach H: Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007, 5(7):749–759.
12. Jorgensen HF, Ben-Porath I, Bird AP: Mbd1 is recruited to both methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell Biol 2004, 24(8):3387–3395.
13. Fujita H, Fuji R, Aratani S, Arano T, Fukamizu A, Nakajima T: Antithetic effects of MBD2a on gene regulation. Mol Cell Biol 2003, 23(8):2645–2657.
14. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pupegacheva E, Hong JA, Morse H 3rd, Schlimok G, Weckermann D, Oberneder R, Fanning E, Riethmüller G: Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005, 65(17):7751–7762.
15. Renova EM, Morse HC 3rd, Ohtson R, Lobanenkov V: The novel BORIS + CTF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002, 12(5):399–414.
16. Renaud S, Pupegacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V: Expression of the CTCF-paralogous cancer-testis genes, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res 2007, 35(21):7372–7388.
17. Pupegacheva EM, Suzuki T, Pack SD, Kosaka-Suzuki N, Yoon J, Vostrov AA, Barsco E, Strunnikov AV, Morse HC 3rd, Loukinov D, Lobanenkov V: The structural complexity of the human BORIS gene in gametogenesis and cancer. PLoS One 2010, 5(11):e13872.
18. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adrani MT, Loukinov DI, Vatolin S, Risinger J, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov V, Schlimok G: Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005, 65(17):7763–7774.
19. Smith IM, Glazer CA, Mathiak SK, Ochs MF, Sun W, Bhan J, Vostrov A, Abdullaev Z, Lobanenkov V, Gray A, Liu C, Chang SS, Ostrow KL, Westra WH, Begum S, Dharma M, Califano J: Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009, 4(3):e4961.
20. Khotnianskikh O, Lioriot A, Brasseur F, De Planer E, De Smet C: Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008, 122(4):777–784.
21. Nguyen P, Bar-Sela G, Sun L, Bisth KS, Cui H, Kohn E, Feinberg AP, Gius D: BART3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone demethylation and gene expression. Mol Cell Biol 2008, 28(21):6720–6729.
22. Sun L, Huang L, Nguyen P, Bisth KS, Bar-Sela G, Ho AS, Bradbury CM, Yu W, Cui H, Lee S, Trepel JB, Feinberg AP, Gius D: DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. Cancer Res 2008, 68(8):2726–2735.
23. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moidenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH: Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 2009, 8(4):2004–2014.
24. Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechstenn-Vollmar M, Schlimok G, Weckermann D, Oberneder R, Fanning E, Riethmüller G: Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995, 87(15):1162–1168.
25. De Smet C, Loriot A, Boon T: Promoter-dependent mechanism leading to selective hypomethylation within the 5’ region of gene MAGE-A1 in tumor cells. Mol Cell Biol, 2004, 24(11):4761–4769.
26. Dahl JA, Collins P, QZChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells. Stem Cells 2007, 25(4):1037–1046.
27. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev J, Zhao K: High-resolution profiling of histone modifications in the human genome. Cell 2007, 129(4):823–837.
28. Santiago FS, Khachigian LM: Ets-1 stimulates platelet-derived growth factor A-chain gene transcription and vascular smooth muscle cell growth via cooperative interactions with Sp1. Circ Res 2004, 95(5):479–487.

29. Emili A, Greenblatt J, Ingles CJ: Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol Cell Biol 1994, 14(3):1582–1593.

30. Kang Y, Hong JA, Chen GA, Nguyen DM, Schrump DS: Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene 2007, 26(30):4394–4403.

31. Majumder S, Kataj H, Datta J, Summers D, Jacob ST, Ghoshal K: Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins. J Cell Biochem 2006, 97(6):1300–1316.

32. Seipel K, Georgiev O, Gerber HP, Schaffner W: C-terminal domain (CTD) of RNA-polymerase II and N-terminal segment of the human TATA binding protein (TBP) can mediate remote and proximal transcriptional activation, respectively. Nucleic Acids Res 1993, 21(24):5609–5615.

33. Schubart DB, Sauter P, Massa S, Friedl EM, Schwarzenbach H, Matthias P: Gene structure and characterization of the murine homologue of the B cell-specific transcriptional coactivator OBF-1. Nucleic Acids Res 1996, 24(10):1913–1920.

34. Woloszyńska-Read A, James SR, Song C, Jin B, Odunsi K, Kopf AR: BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines. Cancer Immun 2010, 106.

35. Cedar H, Bergman Y: Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10(5):295–304.

36. D’Alessio AC, Spyf M: Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 2006, 84(4):463–476.

37. Bhan S, Negi SS, Shao C, Glazer CA, Chuang A, Gaykalova DA, Sun W, Sidransky D, Ha PK, Califano JA: BORIS Binding to the Promoters of Cancer Testis Antigens, MAGEA2, MAGEA3, and MAGEA4, Is Associated with Their Transcriptional Activation in Lung Cancer. Clin Cancer Res 2011, 17(13):4267–4276.

Cite this article as: Schwarzenbach et al.: Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. BMC Cancer 2014 14:796.

doi:10.1186/1471-2407-14-796

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit